Home・Akcijų sąrašas・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

14.93 2.47

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.47

Max

14.8

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-176M 34M
Pardavimai	591K 78M
P/E Sektoriaus vid.	7.112 64.641
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	44.212
Darbuotojai	128
EBITDA	2.7M 50M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+7.55% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-92M 2B
Ankstesnė atidarymo kaina	12.46
Ankstesnė uždarymo kaina	14.93

Naujienos nuotaikos

By Acuity

50%

151 / 340 reitingas Healthcare

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 22:01; UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

2026-08-01 00:01; UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

2026-07-31 21:01; UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

2026-07-30 20:31; UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

2026-07-29 22:01; UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

2026-07-28 19:36; UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

2026-07-27 19:16; UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

2026-07-24 18:26; UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

2026-07-22 19:46; UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

2026-07-21 19:16; UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

2026-07-20 20:01; UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

7.55% į viršų

12 mėnesių prognozė

Vidutinis 15.67 USD 7.55%

Aukščiausias 17 USD

Žemiausias 15 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Aurinia Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

151 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.